Cardiothoracic & vascular anesthesia
Low dose of landiolol does not prevent postoperative atrial fibrillation after cardiac surgery in non-Asian patients: a multicentre randomised study
Primary result · POAF in ICUResult — go to the resultRelative risk 0.93 95% CI 0.67–1.30Authors' conclusion
In non-Asian patients undergoing cardiac surgery with CPB, a low-dose 24-h infusion of landiolol, used as a bridge to oral beta-blockers, did not reduce the incidence of postoperative atrial fibrillation.
Study context
- Population
- Non-Asians ≥65 yr undergoing elective cardiac surgery with cardiopulmonary bypass (CPB) and left ventricular ejection fraction ≥40%, three hospitals in Francerandomised
- Participants
- 318 participants
- Comparison
- Low-dose landiolol infusion vs placebo
- Landiololn = 158
- Placebon = 160reference
- Primary endpoint
- Incidence of POAF while in the ICU
Methodological detailsmulticentre, double-blind, placebo-controlled, superiority, Conducted January 2021 to July 2023
- Multicentre
- Double-blind
- Placebo-controlled
- Superiority
- Conducted January 2021 to July 2023
Primary result
POAF in ICU
Relative risk
0.93
95% CI 0.67–1.30
P = 0.77
Events by treatment group
Landiolol vs Placebo
RR 0.93 (95% CI 0.67–1.30); P = 0.77
As reported in the abstract
Secondary outcomes
Secondary endpoints, including in-hospital postoperative atrial fibrillation (POAF)
- No differences observed
Safety
Safety outcomes
- No differences observed
Original publication
Low dose of landiolol does not prevent postoperative atrial fibrillation after cardiac surgery in non-Asian patients: a multicentre randomised study. Br J Anaesth. Published 6 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →